癌症科学与治疗

Introduction: Breast cancer incidence is rising in our country and most of them are diagnosed at advanced stage. Triple negative subgroup carries dismal prognosis and lacks effective targeted treatment. With this study we have attempted to analyze clinical profile of triple negative breast cancer patient in Jharkhand.
Method: The study was done at HCG; Ranchi from January 2012 to January 2017. All histologically confirmed breast cancer patients were retrospectively included in the study. According to their receptor status they were divided into triple negative subgroup and other group. Their clinic-pathological characteristics and demographic details were compared.
Result: Triple negative subgroup accounts for 1/3rd of total breast cancer patient in Jharkhand. 41% of total tribal breast cancer patients in Jharkhand are triple negative. Most common stage at presentation in both group is stage III.
Conclusion: Effective cancer screening programs and cancer registries are required for adequate planning and execution of cancer programs. Further larger population based studies to study the genetic predisposition of tribal population towards triple negative subgroup.

??????? (OSCC) ???????????????????????????OSCC ??????????????????????? (HR-HPV) ??????HPV ??? OSCC ?????????????????????????????????????????????????????????????????????????????????????? RNA?????????? RNA (sncRNA) ??????????????????????????????????????????????? RNA?? miRNA ? piRNA?????????????????? PIWI ???? RNA (piRNA) ??? sncRNA??????????????????????????????????????????????????????????????????????????????????? pi-RNA ??????????????????????piRNA ????????????/????????????????? OSCC ??????????????????? PIWI-RNA ???????????

????????????????????????????????????????? (PBMC) ??????????????????????????????????? (EOC)????????????????????????????????????????????????????????? PBMC ??????????????????????????????? RNA ?? (RNA-seq) ?????????????? GenBank ???????? (GSE31682) ??????????????????????? (CU-DREAMX) ????????? RNA-seq ????????????????????? 16 ??????? 15 ??????? PBMCs ???????????? GTPase IMAP ???? 8 (GIMAP8) ??????????? GIMAP8 ?????? (p ? < 0.0001)????????????????????????????????? PBMCs ??????????????????????GIMAP8 ?????????????????????????

?????? (NPC) ????????? (I ?) ??????? (II-V ?)?????????????????????????????????????????????????? Jules Bordet ??????????????????????????????
???????????? 2012 ? 5 ?? 2015 ? 9 ???????? 22 ??????? NPC ???????????????? (IMRT) ??????????? (CT)?
??? 13 ?????????9 ???????73% ???????????90% ????????? (III-IVb)?95% ???????? CT ?????????? 31 ???????? 77%??????????????? 95%?86% ? 73%?????? 3 ?????????? (91%)??? (82%)?????? (64%) ??? (23%)????????? 4 ???????????????????????86% ?????????????? 10%?????????????????????3 ?????? (p=0.027)??? (p=0.019) ?????? (p=0.006)????????????????????p=0.042???? 1.62?[95% CI?1.16-2.80]????????????68%???????55%???????????45%???????23%??
????????????????????????????????????? >10% ?????????????????????????????

??????????????????????????????????????????????????????????? (VEGF)?????????????????????????????????????????????????????????????????????????????? VASP ????????????????????????????????????? 50 ????????????????????????????? (???????) ????? I ??????????? 25 ???????????? II ????????????????????????????? (VASP) ?????????????????????????????????? (? I ?) ?? VASP ?????????????????????????????????????? VASP ??????????????????VASP ? ENA/VASP ????????????????????????????????? (???????????)??????? VASP ? ALP ??????????? VASP ?????????????????????? VASP ?????????????????????

??????????????????????????????????? (WBRT)???????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????Khatam ???? CRC1?SBMU2 ????????????????????Azar ???? CRC ??????????????????????????? > 45 ?????? ≤ 3 cm???????????????? 40-44 ?? T=3-4 cm ????? N=0 ???????????????
????216????????????????????????????????323????????????????????????????4??????2??1.06%??1??0.36%??????3???????1??????4??????????3????????1??0????????????????
???????????????p??0.335????IOERT?EBRT??????????????????????????????????????????????????????????????????DCIS?????????